Condition: Solid Tumor · Advanced Solid Tumor · Sponsor: Impact Therapeutics, Inc.
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
This description comes directly from the study's public registry record.
Xiangna Chen · +86-021-68411121 · xiangna.chen@impacttherapeutics.com
Always discuss trial participation with your own doctor first.
| Hackensack University Medical Center PARTNER | Hackensack, New Jersey, United States | Completed |
| Mount Sinai | New York, New York, United States | Completed |
| Greenville Hospital System University Medical Center (ITOR) | Greenville, South Carolina, United States | Completed |
| Mary Crowley Cancer Research Centers | Dallas, Texas, United States | Completed |
| Blacktown Hospital | Blacktown, New South Wales, Australia | Completed |
| Linear Clinical Research Limited | Nedlands, Australia | Completed |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05269316